Clinical Core (Core C) Situated in the Deep South, with prominent footing in rural communities in Alabama and adjacent states, the UAB CFAR Clinical Core (Core C) is uniquely positioned to support scientific inquiries at the interface of prevention and treatment, clinic and community, to hasten an end to HIV/AIDS via the following Specific Aims: 1. To provide Computerized Database and Informatics Services, 2. To provide a comprehensive and efficient Specimen Repository obtained from well-characterized persons living with HIV (PLWH), 3. To provide Study Coordination Services, and 4. To provide comprehensive Biostatistical and Epidemiological Services. Core C has been a cornerstone of the UAB CFAR since its inception, with the UAB 1917 HIV/AIDS Clinic (1917 Clinic) as its focal point. Functioning as a learning healthcare system, observations made at the point of clinical care have driven the scientific initiatives supported by Core C, aligned with the overarching CFAR mission, since 1988. The pursuit of knowledge to address clinically relevant questions has fueled discovery and scholarship that has fed back to the 1917 Clinic to enhance service delivery and treatment outcomes for PLWH, with broad impact nationally and globally. During the last 5-year funding period, Core C generated 780 analysis ready datasets, processed 152,000 specimen vials, and captured 10,800 patient reported outcomes survey assessments at the point of care, while supporting 70 extramural grants and publication of over 300 peer-review manuscripts. A noteworthy milestone, the Clinical Core supported 12 early stage investigators (ESI) from UAB and an additional 10 ESI from other CFARs during the last funding period, who were collectively awarded 15 career development awards (including 11 K awards) and 4 first R01 awards. With a census of roughly 3,500 PLWH, disproportionately African Americans and men who have sex with men, the 1917 Clinic remains the focal point of Core C. However, Clinical Core leadership extends beyond the 1917 Clinic to cultivate unique research platforms via the Jefferson County HIV/AIDS Community Coalition and Alabama Quality Management Group that includes nine HIV clinics statewide providing care for over 6,800 PLWH. Core C innovations include integration of Biostatistical and Epidemiological Services to facilitate synergies and efficiencies, roll out of a user-friendly, web-based REDCap Common Request Form to solicit any (or multiple) core services, and the addition of a Phylogenetic Analysis Database, and Geospatial Database to inform and augment HIV prevention and treatment science. Core C plays a pivotal role enhancing intra- and inter-CFAR collaborations, providing vital research support and leadership to our Interdisciplinary Research Groups and newly formed Ending HIV in Alabama Scientific Working Group, and leveraging synergies with other research Centers, notably the Center for Clinical and Translational Science (UAB CTSA). Ultimately, the Clinical Core mission is to provide ready access to integrated, comprehensive clinical and translational research services to advance HIV prevention and treatment science to promote health equity and hasten an end to HIV/AIDS.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
5P30AI027767-32
Application #
9930530
Study Section
Special Emphasis Panel (ZAI1)
Project Start
Project End
Budget Start
2020-06-01
Budget End
2021-05-31
Support Year
32
Fiscal Year
2020
Total Cost
Indirect Cost
Name
University of Alabama Birmingham
Department
Type
DUNS #
063690705
City
Birmingham
State
AL
Country
United States
Zip Code
35294
Dixit, Saurabh; Sahu, Rajnish; Verma, Richa et al. (2018) Caveolin-mediated endocytosis of the Chlamydia M278 outer membrane peptide encapsulated in poly(lactic acid)-Poly(ethylene glycol) nanoparticles by mouse primary dendritic cells enhances specific immune effectors mediated by MHC class II and CD4+ T cells. Biomaterials 159:130-145
Bengtson, Angela M; Pence, Brian W; Eaton, Ellen F et al. (2018) Patterns of efavirenz use as first-line antiretroviral therapy in the United States: 1999-2015. Antivir Ther 23:363-372
Altekruse, Sean F; Shiels, Meredith S; Modur, Sharada P et al. (2018) Cancer burden attributable to cigarette smoking among HIV-infected people in North America. AIDS 32:513-521
Ladowski, Joseph M; Martens, Gregory R; Reyes, Luz M et al. (2018) Examining the Biosynthesis and Xenoantigenicity of Class II Swine Leukocyte Antigen Proteins. J Immunol 200:2957-2964
Peng, Binghao J; Carlson, Jonathan M; Liu, Michael K P et al. (2018) Antisense-Derived HIV-1 Cryptic Epitopes Are Not Major Drivers of Viral Evolution during the Acute Phase of Infection. J Virol 92:
Shi, Bi; Geng, Jianlin; Wang, Yin-Hu et al. (2018) Foxp1 Negatively Regulates T Follicular Helper Cell Differentiation and Germinal Center Responses by Controlling Cell Migration and CTLA-4. J Immunol 200:586-594
Moshiri, Niema; Mirarab, Siavash (2018) A Two-State Model of Tree Evolution and Its Applications to Alu Retrotransposition. Syst Biol 67:475-489
Crockett, Kaylee B; Rice, Whitney S; Turan, Bulent (2018) Associations Between Multiple Forms of Discrimination and Tobacco Use Among People Living With HIV: The Mediating Role of Avoidance Coping. J Acquir Immune Defic Syndr 78:9-15
Mai, Uyen; Mirarab, Siavash (2018) TreeShrink: fast and accurate detection of outlier long branches in collections of phylogenetic trees. BMC Genomics 19:272
Tomalka, Amanda G; Resto-Garay, Ivelisse; Campbell, Kerry S et al. (2018) In vitro Evidence That Combination Therapy With CD16-Bearing NK-92 Cells and FDA-Approved Alefacept Can Selectively Target the Latent HIV Reservoir in CD4+ CD2hi Memory T Cells. Front Immunol 9:2552

Showing the most recent 10 out of 955 publications